19 March 2024 : Original article
Long-Term Outcomes with Prolonged-Release Tacrolimus in Kidney Transplantation: A Retrospective Real-World Data Analysis
Wilfried Gwinner1ABDE*, Swapneel Anaokar2ACDE, Martin Blogg2ACDE, Birgit Hermann3ACDE, Carola del Pilar Repetur2CDE, Mario Schiffer4ABDEDOI: 10.12659/AOT.942167
Ann Transplant 2024; 29:e942167
Table 8 Laboratory assessments at 8–12 weeks after transplant by population cohort.
| Parameter | Cohort | |||
|---|---|---|---|---|
| De novo (n=92) | Early conversion (n=12) | Late conversion (n=48) | All patients (N=152) | |
| Mean (SD) serum creatinine (mg/mL) | 1.70 (0.74) | 1.43 (0.64) | 1.66 (0.46) | 1.67 (0.65) |
| Mean (SD) eGFR (mL/min/1.73 m)* | 43.45 (12.37) | 50.73 (19.73) | 44.94 (13.04) | 44.49 (13.32) |
| Mean (SD) CKD-EPI (mL/min/1.73 m) | 49.10 (18.52) | 62.13 (24.47) | 50.18 (17.47) | 50.47 (18.91) |
| Mean (SD) tacrolimus trough level (ng/mL) | 10.00 (3.04) | 12.13 (5.84) | 10.75 (3.12) | 10.41 (3.39) |
| CKD-EPI – Chronic Kidney Disease Epidemiology Collaboration; eGFR – estimated glomerular filtration rate; SD – standard deviation. * Estimated using modification of diet in renal disease-4 (MDRD-4) method. | ||||